Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Non-Hodgkin × etoposide phosphate × Clear all

Phase

Phase 2 10 Phase 1/2 2 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 4 Central Nervous System Neoplasms 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Neoplasms, Germ Cell and Embryonal 2 Lung Neoplasms 2 Leukemia 2 Hodgkin Disease 2 Brain Neoplasms 2 Teratoma 1 Seminoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Ovarian Germ Cell Cancer 1 Nonseminomatous germ cell tumor 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Multiple Myeloma 1 Malignant mesenchymal tumor 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1

Interventions

Rituximab 53 Cyclophosphamide 32 Vincristine 24 Doxorubicin 22 Prednisone 20 Bendamustine Hydrochloride 16 Etoposide 13 Radiotherapy 11 Cytarabine 9 ibrutinib 6 fludarabine 6 VAP-cyclo protocol 6 Prednisolone 6 Peripheral Blood Stem Cell Transplantation 6 Granulocyte Colony-Stimulating Factor 6 Gemcitabine 6 Filgrastim 6 pirtobrutinib 5 ibritumomab tiuxetan 5 Methotrexate 5 Melphalan 5 Lenalidomide 5 pixantrone 4 Mitoxantrone 4 Epoetin Alfa 4 Cyclosporine 4 Carmustine 4 Bleomycin 4 venetoclax 3 tositumomab I-131 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡